Literature DB >> 16305589

Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study.

Adrianne Faber1, Marcel L Bouvy, Linda Loskamp, Paul B van de Berg, Toine C G Egberts, Lolkje T W de Jong-van den Berg.   

Abstract

AIMS: To estimate the diffusion of new safety information concerning postmenopausal hormonal replacement therapy (HRT) into prescribing practice in The Netherlands and to assess the impact of revised guidelines on the long-term treatment of HRT.
DESIGN: Cross-sectional study.
SETTING: Community pharmacy dispensing data from a population of approximately 450,000 patients in the northern and eastern part of The Netherlands. POPULATION: Women aged 45-69 years to whom at least one HRT prescription was dispensed between 1 January 2000 and 1 January 2004. MAIN OUTCOME MEASURES: Annual and quarter prevalences of HRT and the proportion of new HRT users, switchers and continuous HRT users per quarter.
RESULTS: The prevalence of HRT prescribing decreased significantly from 107/1000 [95% confidence interval (CI) 104, 110] in 2000 to 87/1000 (95% CI 84, 89) in 2003. The decreasing prevalence was especially evident among the younger age groups and was most pronounced among users of oestrogen/progestagen combinations. The publication of the Women Health Initiative Study (WHI) was followed by a modest decrease in prescribing of HRT, whereas prescribing of HRT declined dramatically after publication of the Million Women Study (MWS) in August 2003. Among the continuous HRT users in the 4th quarter of 2002, 55% used HRT longer than 3 years. This percentage was 53 in the 4th quarter of 2003.
CONCLUSIONS: In contrast to the release of the WHI study results, publication of the MWS was followed by a dramatic fall in prescribing of HRT in The Netherlands. Despite the new recommendation that long-term HRT use should be discouraged, the proportion of long-term users did not change after the publication of the MWS.

Entities:  

Mesh:

Year:  2005        PMID: 16305589      PMCID: PMC1884890          DOI: 10.1111/j.1365-2125.2005.02502.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Hormone replacement therapy for secondary prevention of coronary heart disease.

Authors:  C X Pan; J Boal
Journal:  JAMA       Date:  1999-03-03       Impact factor: 56.272

2.  Breast cancer and hormone-replacement therapy: up to general practice to pick up the pieces.

Authors:  Toine Lagro-Janssen; Walter W Rosser; Chris van Weel
Journal:  Lancet       Date:  2003-08-09       Impact factor: 79.321

3.  Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users.

Authors:  Beverley Lawton; Sally Rose; Deborah McLeod; Anthony Dowell
Journal:  BMJ       Date:  2003-10-11

4.  [Hormone replacement therapy in the peri-menopausal and post menopausal period: more than half of the women were treated for more than one year].

Authors:  H Tobi; P B van den Berg; J R Brouwers; L T de Jong-van den Berg
Journal:  Ned Tijdschr Geneeskd       Date:  2003-09-20

5.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Authors:  Sally A Shumaker; Claudine Legault; Stephen R Rapp; Leon Thal; Robert B Wallace; Judith K Ockene; Susan L Hendrix; Beverly N Jones; Annlouise R Assaf; Rebecca D Jackson; Jane Morley Kotchen; Sylvia Wassertheil-Smoller; Jean Wactawski-Wende
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

6.  Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results.

Authors:  Jennifer S Haas; Celia P Kaplan; Eric P Gerstenberger; Karla Kerlikowske
Journal:  Ann Intern Med       Date:  2004-02-03       Impact factor: 25.391

7.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

8.  Breast cancer and hormone-replacement therapy in the Million Women Study.

Authors:  Valerie Beral
Journal:  Lancet       Date:  2003-08-09       Impact factor: 79.321

9.  National use of postmenopausal hormone therapy: annual trends and response to recent evidence.

Authors:  Adam L Hersh; Marcia L Stefanick; Randall S Stafford
Journal:  JAMA       Date:  2004-01-07       Impact factor: 56.272

10.  Influences of educational interventions and adverse news about calcium-channel blockers on first-line prescribing of antihypertensive drugs to elderly people in British Columbia.

Authors:  M Maclure; C Dormuth; T Naumann; J McCormack; R Rangno; C Whiteside; J M Wright
Journal:  Lancet       Date:  1998-09-19       Impact factor: 79.321

View more
  15 in total

Review 1.  Postmenopausal hormone therapy and breast cancer risk: current status and unanswered questions.

Authors:  Wendy Y Chen
Journal:  Endocrinol Metab Clin North Am       Date:  2011-07-12       Impact factor: 4.741

2.  Is transdermal menopausal hormone therapy a safer option than oral therapy?

Authors:  Bette Liu
Journal:  CMAJ       Date:  2013-03-18       Impact factor: 8.262

3.  Recent Trends in Breast Cancer Incidence and Mortality in Germany.

Authors:  Alexander Katalinic; Ron Pritzkuleit; Annika Waldmann
Journal:  Breast Care (Basel)       Date:  2009-04-24       Impact factor: 2.860

Review 4.  Mind-body therapies for menopausal symptoms: a systematic review.

Authors:  Kim E Innes; Terry Kit Selfe; Abhishek Vishnu
Journal:  Maturitas       Date:  2010-02-18       Impact factor: 4.342

5.  Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005.

Authors:  Joanna Watson; Lesley Wise; Jane Green
Journal:  Eur J Clin Pharmacol       Date:  2007-06-28       Impact factor: 2.953

Review 6.  Why do stress and urge incontinence co-occur much more often than expected?

Authors:  Vatche A Minassian; Walter F Stewart; Annemarie G Hirsch
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-06-05

Review 7.  Exogenous and endogenous hormones and breast cancer.

Authors:  Wendy Y Chen
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-08       Impact factor: 4.690

Review 8.  SERMs for the treatment and prevention of breast cancer.

Authors:  Ramona F Swaby; Catherine G N Sharma; V Craig Jordan
Journal:  Rev Endocr Metab Disord       Date:  2007-09       Impact factor: 6.514

9.  Gender differences in colorectal cancer: implications for age at initiation of screening.

Authors:  H Brenner; M Hoffmeister; V Arndt; U Haug
Journal:  Br J Cancer       Date:  2007-02-20       Impact factor: 7.640

10.  Differences in menopausal hormone therapy use among women in Germany between 1998 and 2003.

Authors:  Yong Du; Martina Dören; Hans-Ulrich W Melchert; Christa Scheidt-Nave; Hildtraud Knopf
Journal:  BMC Womens Health       Date:  2007-10-18       Impact factor: 2.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.